New Firm Mereo Gets Novartis Compounds | Chemical & Engineering News
Volume 93 Issue 31 | p. 23 | Concentrates
Issue Date: August 3, 2015

New Firm Mereo Gets Novartis Compounds

Department: Business

Mereo BioPharma has been formed to acquire three clinical-stage compounds from Novartis. London-based Mereo simultaneously raised $119 million from investors, including Novartis, and acquired BPS-804, a monoclonal antibody for brittle bone syndrome; BCT-197, a small-molecule drug for lung disease; and BGS-649, a small molecule for obese men with abnormal testosterone levels. Mereo says it formed “to take advantage of the global pharmaceutical industry’s drive for creative ways to progress their clinical development pipelines.”

Chemical & Engineering News
ISSN 0009-2347
Copyright © American Chemical Society

Leave A Comment

*Required to comment